Welcome back to the SteadyTrade Podcast!

‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ [Alternate text] GLP-1: The Game-Changer Investors Can't Ignore Hey, GLP-1 medications are a hot topic right now. Drugs like Novo Nordisk's (NVO) Ozempic and Eli Lilly's (LLY) Mounjaro are not only transforming individuals' weight loss and overall health… they're also presenting significant economic opportunities. On today's episode of the SteadyTrade Podcast, Tim Bohen and Matt McCall explore the revolutionary impact of these medications. Unlike traditional weight-loss methods – which can be challenging due to people's busy lifestyles – GLP-1 medications lower the barriers to achieving a healthier weight and offer a more accessible and effective solution. This boosts the user's physical health and productivity. The economic impact of these drugs has been immense. According to Goldman Sachs, we can expect to see a significant boost to the economy – not just through sales but via enhanced productivity. It's a self-fulfilling cycle. As a result, the market potential for these drugs is massive. Drug manufacturers like Novo Nordisk and Eli Lilly will see substantial growth. In fact, Novo has already become the largest company in European as a result. But these two companies are far from the only investment opportunities in the GLP-1 medication space… Smaller players like Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are worth keeping an eye on. In fact, Viking's rise from its penny-stock beginning illustrates the potential for high returns in this sector. We also talk about the importance of investing in supply-chain businesses like McKesson (MCK) and Cencora (COR). These firms play a crucial role in the distribution of these medications and provide another avenue to capitalize on their growth. There are also secondary opportunities to explore – like the increased demand for protein among GLP-1 medication users. There's no question that these drugs offer a promising solution to the obesity epidemic and present significant economic benefits through increased productivity and market growth. With a wealth of investment potential in pharmaceutical giants, supply-chain companies, and protein supplement producers, the impact of GLP-1 medications will be felt across a variety of sectors. This makes it an exciting area to watch for both health enthusiasts and investors. If you're either of those – or just want to hear our take on the topic – [Click here to watch the latest episode of the SteadyTrade Podcast now.]( [[ratio]  ]( Here’s to the future, Tim Bohen Lead Trainer, StockToTrade Matt McCall Editor, Market Insights     [Click Here to Unsubscribe]( 13809 Research Boulevard, Suite 500, Austin, TX 78750 **Tim Bohen teaches skills others have used to make money. Any results displayed are extraordinary and are not typical and will vary from person to person. For more info read our [Earning Claims Disclosure]( About: Making money trading stocks takes time, dedication, and hard work. My goal is to teach you how I have succeeded in the market, but you may not achieve my results. Remember, there are risks involved with investing, including the potential loss of money. We are strongly committed to protecting your privacy and providing a safe & high-quality online experience for all of our visitors. We understand that you care about how the information you provide to us is used and shared. We have developed a Privacy Policy to inform you of our policies regarding the collection, use, and disclosure of information we receive from users of our website. Our Privacy Policy, along with our Term & Conditions, governs your use of this site. By using our site, or by accepting the Terms of Use (via opt-in, checkbox, pop-up, or clicking an email link confirming the same), you agree to be bound by our Terms & Conditions and our Privacy Policy. If you have provided personal, billing, or other voluntarily provided information, you may access, review, and make changes to it via instructions found on the Website or by replying to this email. To manage your receipt of marketing and non-transactional communications, you may unsubscribe by clicking the “unsubscribe” link located on the bottom of any marketing email. Emails related to the purchase or delivery of orders are provided automatically – Customers are not able to opt out of transactional emails. We will try to accommodate any requests related to the management of Personal Information in a timely manner. However, it is not always possible to completely remove or modify information in our databases (for example, if we have a legal obligation to keep it for certain timeframes, for example). If you have any questions, simply reply to this email or visit our website to view our official policies. Copyright © StocksToTrade.com